Wed, February 15, 2012
Tue, February 14, 2012
Mon, February 13, 2012
Sun, February 12, 2012
Fri, February 10, 2012
Thu, February 9, 2012
Wed, February 8, 2012
[ Wed, Feb 08th 2012 ]: Market Wire
Imaging3 Updates Website
Tue, February 7, 2012
Mon, February 6, 2012
Sun, February 5, 2012
[ Sun, Feb 05th 2012 ]: Market Wire
30 a.m. ET
Sat, February 4, 2012
Fri, February 3, 2012
Thu, February 2, 2012

Orexigen Therapeutics to Present at Upcoming Conferences


  Copy link into your clipboard //health-fitness.news-articles.net/content/2012/ .. apeutics-to-present-at-upcoming-conferences.html
  Print publication without navigation Published in Health and Fitness on by Market Wire
          🞛 This publication is a summary or evaluation of another publication

Orexigen Therapeutics to Present at Upcoming Conferences -- SAN DIEGO, Feb. 9, 2012 /PRNewswire/ --

Orexigen Therapeutics to Present at Upcoming Conferences

[ ]

SAN DIEGO, Feb. 9, 2012 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: [ OREX ]) today announced that management will be presenting at two upcoming investor conferences.  The details are as follows:

The 14th Annual BIO CEO & Investor Conference
Date:  February 13, 2012
Time:  1:30pm Eastern Time
Location:  Waldorf Astoria, New York
Speaker:  Michael Narachi, President and Chief Executive Officer

Leerink Swann Global Healthcare Conference
Date:  February 15, 2012
Time:  8:00am Eastern Time
Location:  Waldorf Astoria, New York
Speaker:  Michael Narachi, President and Chief Executive Officer

To listen to the live webcast or a replay of the presentations, please visit the Investor Relations section of the company's Web site at [ www.orexigen.com ]. A replay will be available for 14 days after the event.

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. Contrave® has completed Phase 3 clinical trials for which a New Drug Application has been submitted and reviewed by the FDA, and the FDA has agreed to a SPA for the Contrave outcomes trial.  The Company's other product candidate, Empatic™, has completed Phase 2 clinical trials. Further information about the Company can be found at [ www.orexigen.com ].

Corporate Contacts: Orexigen

cellpadding="0" cellspacing="0" id="convertedTable" style="BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt; BORDER-COLLAPSE: collapse; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">

Orexigen

Media

Jay Hagan

Denise Powell

Chief Business Officer

WCG

(858) 875-8673

(510) 703-9491

 

SOURCE Orexigen Therapeutics, Inc.

[ Back to top ]

RELATED LINKS
[ http://www.orexigen.com ]


Publication Contributing Sources